---

---

tags : Application    entities : Incyte corporation   

save search

---

Innovent's First New Drug Application of Mazdutide for Chronic Weight Management has been Accepted by the NMPA of China
Published: 2024-02-07 (Crawled : 09:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M |

Health Technology

| 3.02% | O: 0.76% H: 4.31% C: 2.11%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -0.49% | O: 1.33% H: 0.0% C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -12.21% | O: -0.65% H: 0.57% C: -3.21%
first management drug application china

---

China's First NDA for a KRAS G12C Inhibitor: Innovent Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for IBI351
Published: 2023-11-24 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| -0.32% | O: 0.69% H: 1.66% C: 1.66%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -0.28% | O: 1.46% H: 0.0% C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -1.97% | O: 0.34% H: 0.37% C: 0.3%
ibi351 drug granted review designation medical application china

---

AnHeart Therapeutics and Innovent Announce China’s NMPA Has Accepted a New Drug Application for Taletrectinib (ROS1 Inhibitor)
Published: 2023-11-22 (Crawled : 17:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| -0.36% | O: -0.74% H: 0.71% C: 0.71%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -0.62% | O: -0.34% H: 0.0% C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -1.65% | O: 0.56% H: 1.06% C: -0.24%
drug application therapeutics

---

Innovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Accepted the New Drug Application for Taletrectinib (ROS1 Inhibitor)
Published: 2023-11-22 (Crawled : 13:30) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| -0.36% | O: -0.74% H: 0.71% C: 0.71%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -0.62% | O: -0.34% H: 0.0% C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -1.65% | O: 0.56% H: 1.06% C: -0.24%
drug medical application therapeutics china

---

Innovent Announces the National Medical Products Administration in China Has Accepted and Granted Priority Review Designation to the New Drug Application for Parsaclisib (PI3Kδ inhibitor) for the Treatment of Relapsed or Refractory Follicular Lymphoma
Published: 2023-01-06 (Crawled : 05:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| -6.17% | O: -0.35% H: 0.0% C: -2.69%
LLY | News | $726.31 -2.63% -0.04% 3.5M |

Health Technology

| 102.36% | O: 0.3% H: 1.86% C: 0.82%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -3.02% | O: 0.02% H: 0.0% C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -34.69% | O: 1.05% H: 0.2% C: -0.16%
treatment designation drug medical application granted review china

---

Innovent and Ascentage Pharma Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML
Published: 2022-07-19 (Crawled : 01:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M |

Health Technology

| 125.72% | O: 0.72% H: 1.02% C: 0.65%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -34.97% | O: -0.83% H: 0.0% C: 0.0%
treatment designation pharma drug application granted review china

---

Innovent and Ascentage Pharma Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML
Published: 2022-07-20 (Crawled : 01:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M |

Health Technology

| 122.66% | O: 0.27% H: 0.22% C: -1.55%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -34.42% | O: 2.32% H: 1.21% C: 0.99%
treatment designation pharma drug application granted review china

---

Ascentage Pharma and Innovent Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML
Published: 2022-07-19 (Crawled : 17:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M |

Health Technology

| 125.72% | O: 0.72% H: 1.02% C: 0.65%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -34.97% | O: -0.83% H: 0.0% C: 0.0%
treatment designation pharma drug application granted review china

---

Innovent Announces the NMPA Acceptance of the New Drug Application for Tafolecimab Injection (anti-PCSK-9 antibody)
Published: 2022-06-14 (Crawled : 01:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M |

Health Technology

| 149.94% | O: -0.49% H: 0.98% C: 0.56%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -24.06% | O: -2.09% H: 0.41% C: -1.96%
drug application injection

---

Innovent and IASO Bio Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Published: 2022-06-06 (Crawled : 01:00) - prnewswire.com
SANA | $7.605 -1.62% -1.64% 3.4M |

| 40.93% | O: 5.56% H: 2.46% C: -13.16%
LLY | News | $726.31 -2.63% -0.04% 3.5M |

Health Technology

| 139.67% | O: 3.83% H: 0.0% C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -29.78% | O: 0.01% H: 0.0% C: 0.0%
treatment drug application

---

IASO Bio and Innovent Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Published: 2022-06-02 (Crawled : 17:00) - biospace.com/
SANA | $7.605 -1.62% -1.64% 3.4M |

| 42.91% | O: -6.1% H: 9.2% C: 8.6%
LLY | News | $726.31 -2.63% -0.04% 3.5M |

Health Technology

| 132.17% | O: -0.9% H: 0.0% C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -30.18% | O: -0.4% H: 0.25% C: -0.07%
treatment drug application

---

Incyte Announces U.S. FDA Has Extended the Supplemental New Drug Application Review Period for Ruxolitinib Cream (Opzelura™) for the Treatment of Vitiligo
Published: 2022-03-14 (Crawled : 13:30) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -29.2% | O: -0.3% H: 0.85% C: -2.08%
new drug treatment fda application ces drug

---

Innovent Announces NMPA of China Acceptance of a Supplemental New Drug Application for TYVYT®
Published: 2021-12-24 (Crawled : 14:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| Email alert Add to watchlist
LLY | News | $726.31 -2.63% -0.04% 3.5M |

Health Technology

| Email alert Add to watchlist
tyvyt new drug application drug china

---

Innovent Announces NMPA of China Acceptance of a Supplemental New Drug Application for TYVYT® (Sintilimab Injection plus Bevacizumab Biosimilar Injection and Chemotherapy in Patients with EGFR-mutated Non-squamous Non-small Cell Lung Cancer who Progressed after EGFR-TKI Therapy
Published: 2021-12-24 (Crawled : 11:00) - prnewswire.com
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| Email alert Add to watchlist
LLY | News | $726.31 -2.63% -0.04% 3.5M |

Health Technology

| Email alert Add to watchlist
tyvyt new drug application drug cel lung cancer china therapy injection cancer biosimilar

---

Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with Chemotherapy as First-Line Treatment for Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Published: 2021-11-04 (Crawled : 09:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M |

Health Technology

| 181.41% | O: 3.16% H: 0.0% C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -18.96% | O: 2.41% H: 0.0% C: 0.0%
new drug treatment application therapy drug

---

Incyte Announces the Validation of the European Marketing Authorization Application for Ruxolitinib Cream in Vitiligo
Published: 2021-10-28 (Crawled : 12:15) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -19.42% | O: 0.49% H: 1.01% C: 0.69%
europe application

---

Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis
Published: 2021-06-11 (Crawled : 12:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -40.19% | O: -3.27% H: 0.39% C: -2.47%
new drug treatment fda dermatitis drug atopic dermatitis application

---

Gainers vs Losers

67%

33%

Top 10 Gainers

AGBA | News | $1.26 215.0% 68.25% 130M |

Finance

EGOX | $0.0515 43.06% 30.1% 330M |

OLB 4 | $0.33 -14.95% 25.53% 840K |

Technology Services

NVFY | $2.77 31.28% 23.83% 33M |

Consumer Durables

ZCMD | $1.87 28.97% 22.46% 31M |

Commercial Services

RCON | $0.1112 13.01% 21.28% 1.7M |

Distribution Services

INSG | $3.03 25.21% 20.13% 330K |

Electronic Technology

GCTK | $0.8191 22.25% 18.2% 190K |

Manufacturing

WLGS | $0.59 18.0% 17.9% 2.3M |

ASNS | $0.828 21.75% 17.86% 18K |

---

Your saved searches

---